Latest Pharmaceuticals News

Page 5 of 89
Clarity Pharmaceuticals has completed planned recruitment for its 383-participant CLARIFY Phase III trial of 64Cu-SAR-bisPSMA, moving the diagnostic candidate into patient follow-up. Topline sensitivity and specificity data are expected in the first half of 2027 and could support a US FDA application.
Ada Torres
Ada Torres
27 Oct 2026
Argent BioPharma has granted Thai Phytomed International exclusive global commercialisation rights to four cannabis genotypes under a 10-year agreement. The deal preserves Argent’s ownership, but royalties depend on TPI generating profitable sales and securing approvals across multiple markets.
Victor Sage
Victor Sage
27 Oct 2026
AdAlta is nearing two important development milestones for its EW-001 CAR-T therapy, with a US FDA pre-IND meeting scheduled for 4 November and Australian manufacturing runs expected before year-end. The progress comes with encouraging but early Chinese clinical data, while cash of A$0.65 million leaves limited room for delay.
Ada Torres
Ada Torres
26 Oct 2026
Island Pharmaceuticals has secured approvals to use Galidesivir in Uganda’s Bundibugyo Ebola outbreak while advancing two complementary Marburg studies and expanding manufacturing. The progress comes with a sharper funding question: cash fell to A$7.83 million after quarterly operating outflows of A$4.93 million, leaving an estimated 1.6 quarters of funding.
Victor Sage
Victor Sage
26 Oct 2026
Mayne Pharma’s unaudited first-quarter revenue fell 2% to A$95.7 million, while underlying EBITDA dropped 52% as generic competition hit Dermatology. Strong prescription growth in Women’s Health and DistributeRx offered a partial counterweight, alongside progress on key legal disputes.
Victor Sage
Victor Sage
26 Oct 2026
Hydration Pharmaceuticals is asking eligible shareholders for up to A$1.43 million in fresh capital as it funds the next phase of its turnaround. The non-renounceable offer comes with free options, but is neither underwritten nor subject to a minimum subscription.
Ada Torres
Ada Torres
23 Oct 2026
Firebrick Pharma is escalating Nasodine’s US push from online sales into retail pharmacies while its September-quarter cash balance fell to A$875,000. The company reported a A$398,000 operating cash outflow and estimated 2.2 quarters of funding at the current rate.
Victor Sage
Victor Sage
23 Oct 2026
Argent BioPharma ended the September quarter with just A$11,000 in cash after A$734,000 of operating outflows, despite retaining A$7.4 million of unused convertible financing capacity. The company is simultaneously expanding its commercial portfolio through NLC antiviral rights and a CannEpil veterinary programme.
Victor Sage
Victor Sage
23 Oct 2026
Amplia Therapeutics has received an A$4.78 million refundable R&D tax rebate, giving the clinical-stage biotechnology company additional cash to advance its FAK inhibitor programs. The funds will support multiple narmafotinib trials and related research, including studies involving Lilly.
Victor Sage
Victor Sage
22 Oct 2026
Recce Pharmaceuticals has granted Arrotex exclusive rights to commercialise its investigational RECCE 327 topical gel in Australia and New Zealand. The agreement offers a potential profit-share stream, but no upfront payments, sales forecast or approval have been disclosed.
Ada Torres
Ada Torres
22 Oct 2026
CSL has appointed ViiV Healthcare CEO Deborah Waterhouse to lead the biopharmaceutical group from 1 February 2027. Her arrival comes with a substantial UK-pound-denominated remuneration package and a mandate to renew the pipeline while simplifying operations.
Ada Torres
Ada Torres
21 Oct 2026
BLS Pharmaceuticals has started FY27 with its strongest quarter on record, reporting A$26.7 million in unaudited revenue and positive operating cash flow. The company reaffirmed its A$105 million to A$115 million revenue guidance while continuing to invest in Australian and Scottish manufacturing capacity.
Victor Sage
Victor Sage
21 Oct 2026

Browse the archive

Full archive